CLLever
.png)
Series of Webinars on Chronic Lymphocytic Leukemia (CLL)
Learning objectives are to provide answers to the questions below:
2. What’s the mechanism of BTKi resistance?
3. How to identify patients with resistance to BTKi?
4. How to cope with resistance to BTKi? Do we have any successful examples of management of BTKi resistance for CLL patients?
5. How to manage different groups of CLL patients?
6. Is it possible and acceptable to refuse immunochemotherapy in CLL treatment?.
7. What are the clinical trial results and how do they impact the real treatment practice?
8. How are the patients with Richter syndrome diagnosed and treated?
9. What are the important side effects to be aware of when prescribing BTKi? How to minimize the risk of their occurrence and what to do when these events occur?
July 2025
1 CE credit
Webinar 1: Resistance of BTK Inhibitors in Treating Chronic Lymphocytic Leukemia
Mutations in BTK and downstream kinases can cause resistance to covalent BTK inhibitors. This resistance often arises through several mechanisms, with a common one being a mutation in BTK that substitutes an amino acid, thereby disrupting the covalent bond between the BTK kinase domain and the inhibitor. Resistance can emerge through various mechanisms, including acquired mutations in the BTK C481 residue, which is the binding site for covalent BTK inhibitors. Noncovalent (reversible) BTK inhibitors overcome this mechanism and other sources of resistance, but the mechanisms of resistance to these therapies are currently not well understood. Even non-covalent BTK inhibitors acquire resistance through mutations in BTK outside the C481 residue and mutations in PLCγ2.
August, 2025
1 CE credit
Webinar 2: Resistance to BTK Inhibitors: Identifying Risk Factors and Diagnostics
It is crucial to explore the genomic variations, and the associated pathways involved in cancer pathophysiology to understand the mechanisms of resistance of BTK inhibitors; to identify patients with BTKi resistance and management of such patients; to increase the understanding of BTKi in combination of CD20 immunotherapy, and chimeric antigen receptor T cell with BTKi combination therapy.
September, 2025
1 CE credit
Webinar 3: CLL Patients’ Management: Treatment of High Risk or Relapsed CLL
Join the discussion of current treatment landscape of CLL in the high-risk and relapse setting; the role of chemoimmunotherapy, BTK inhibitors and its potential use for monotherapy; treatment alternatives; and an overview of clinical trial data for BTK inhibitors and chemoimmunotherapy.
October, 2025
1 CE credit
Webinar 4: Risk Factors, Molecular Pathogenesis, and Prognosis of Richter Syndrome
Richter transformation (RT) is the progression of CLL into an aggressive lymphoproliferative disorder, most commonly manifesting as diffuse large B-cell lymphoma (DLBCL). While recent advancements have led to the development of novel therapies for RT, it remains an area of significant unmet medical need. There is a pressing demand for new approaches to improve the diagnosis, treatment, and management of this progression.
November, 2025
1 CE credit
Webinar 5: Long-term Safety of CLL treatment – Management of Risks
Join the discussion of side effects encountered with CLL treatments; prevention and management techniques of them; methodologies for educating patients; and approaches to treatment discontinuation for CLL patients.
